Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Filgotinib, a Selective JAK‐1 Inhibitor, After Short‐Term Treatment of Rheumatoid Arthritis: Results of Two Randomized Phase IIa Trials

201777 citationsJournal Articlehybrid Open Access

Authors

Selective inhibition of JAK-1 with filgotinib shows initial efficacy in RA with an encouraging safety profile in these exploratory studies.

Good health and well-being

Published in: Arthritis & Rheumatology

Volume 69, Issue 10, pp. 1949-1959

Field-Weighted Citation Impact: 4.95